| CAS No.: | 59-05-2 |
|---|---|
| Formula: | C20h22n8o5 |
| EINECS: | 200-413-8 |
| Type: | Pharmaceutical Intermediates |
| Appearance: | Powder |
| Quality: | Industrial |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier
| Product Name | Methotrexate |
| Melting point | 195°C |
| BRN | 70669 |
| EINECS | 200-413-8 |
Methotrexate is used as a disease-modifying treatment for some autoimmune diseases, including rheumatoid arthritis, juvenile dermatomyositis, psoriasis, psoriatic arthritis, lupus, sarcoidosis, Crohn's disease (although a recent review has raised the point that it is fairly underused in Crohn's disease), eczema and many forms of vasculitis. Although originally designed as a chemotherapy drug (using high doses), in low doses, methotrexate is a generally safe and well tolerated drug in the treatment of certain autoimmune diseases. Because of its effectiveness, low-dose methotrexate is now first-line therapy for the treatment of rheumatoid arthritis. Weekly doses are beneficial for 12 to 52 weeks duration therapy, although discontinuation rates are as high as 16% due to adverse effects. Although methotrexate for autoimmune diseases is taken in lower doses than it is for cancer, side effects such as hair loss, nausea, headaches, and skin pigmentation are still common. Use of low doses of methotrexate together with NSAIDS such as aspirin or paracetamol is relatively safe in people being treated for rheumatoid arthritis, if adequate monitoring is done.
Any questions or requirement , Feel free to Contact Us to Get Professsional Service
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}